Lucid Diagnostics Inc.
LUCD
Rank in Stocks
#20723
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on... Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Share Price
$0.4175
Last synced: 2026-11-09
Market Cap
$79.72M
Change (1 day)
4.90%
Change (1 year)
-59.86%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lucid Diagnostics Inc. (LUCD)
Category
Healthcare
EPS for Lucid Diagnostics Inc. (LUCD)
EPS as of June 2026 TTM: $-0.47
According to Lucid Diagnostics Inc.'s latest financial reports, its current EPS (TTM) is $-0.47. At the end of 2025 the company had an EPS of $-0.69, an increase over its 2024 EPS of $-1.05.
EPS history for Lucid Diagnostics Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.47 | -31.88% |
| 2025 | $-0.69 | -34.29% |
| 2024 | $-1.05 | -16.67% |
| 2023 | $-1.26 | -18.71% |
| 2022 | $-1.55 | 98.72% |
| 2021 | $-0.78 | 254.55% |
| 2020 | $-0.22 | 83.33% |
| 2019 | $-0.12 | 294.74% |
| 2018 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | -674.47% |
US
|
|
| $4.09 | -970.21% |
IE
|
|
| $9.45 | -2,110.64% |
US
|
|
| $2.37 | -604.26% |
US
|
|
| $1.77 | -476.60% |
US
|
Questions about Lucid Diagnostics Inc.'s earnings per share (EPS)
What is Lucid Diagnostics Inc.'s earnings per share (EPS)?
Lucid Diagnostics Inc.'s earnings per share (EPS) over the last twelve months is $-0.47, as of Jun 2026.
What was Lucid Diagnostics Inc.'s earnings per share (EPS) in 2025?
In 2025, Lucid Diagnostics Inc.'s earnings per share (EPS) was $-0.69, compared with $-1.05 in 2024.
How has Lucid Diagnostics Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Lucid Diagnostics Inc.'s earnings per share (EPS) was highest in 2020 ($-0.22) and lowest in 2022 ($-1.55).
How does Lucid Diagnostics Inc.'s earnings per share (EPS) compare with similar companies?
Lucid Diagnostics Inc.'s earnings per share (EPS) ($-0.47) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.